| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| XBiotech Inc. | Natrunix | Rheumatoid Arthritis | Phase 2 | Data Released | Intravenous | Immunology: Anti-TNF |
| Xencor Inc. | XmAb5871 | Systemic Lupus Erythematosus (SLE) | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| Xenetic Biosciences Inc. | Epolong | Anemia in patients with chronic kidney disease (CKD) | Phase 3 | Trial Completed | Oral | Anti-Anemia |
| Xenetic Biosciences Inc. | XBIO-101 | Endometrial cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Xenon Pharmaceuticals Inc. | azetukalner (XEN1101) - (X-NOVA) | Major depressive disorder (MDD) | Phase 3 | Ongoing | oral | Psychiatric |
| Xenon Pharmaceuticals Inc. | Azetukalner (XEN1101) - (X-TOLE2) | Adult Focal Epilepsy | Phase 3 | Data Released | Oral | Neurology |
| Xenon Pharmaceuticals Inc. | XEN496 - (EPIK) | Epilepsy | Phase 3 | Trial Discontinued | Oral | Neurology |
| Xenon Pharmaceuticals Inc. | Azetukalnerm - (X-ACKT) | Epilepsy indication of primary generalized tonic-clonic seizures (PGTCS) | Phase 3 | Ongoing | Intravenous | Neurology |